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TLR4Diabetic cardiomyopathy (DiCM) is characterized bymyocardial ﬁbrosis and dysfunction. In rodentmodels of di-
abetes myocardial HMGB1 increases while IL-33 decreases. The major cardiac cell type expressing HMGB1 is the
myocyte while the primary IL-33 expressing cell is the ﬁbroblast. The aim of this study was to delineate the ex-
tracellular communication pathway(s) between cardiomyocytes and ﬁbroblasts that contributes to murine
DiCM. The streptozotocin (STZ)-induced murine model of diabetes and a cardiomyocyte/ﬁbroblast co-culture
challenged with high glucose were used. In STZ mice, myocardial HMGB1 expression was increased while IL-
33 expression decreased (immunoﬂuorescence andWestern blot). In addition, STZ mice had an increased myo-
cardial collagen deposition and myocardial dysfunction (pressure-volume loop analysis). An HMGB1 inhibitor
(A-box) or exogenous IL-33 prevented the myocardial collagen deposition and dysfunction. In the cardiomyo-
cyte/ﬁbroblast co-culture model, HG increased cardiomyocyte HMGB1 secretion, decreased ﬁbroblast IL-33 ex-
pression, and increased ﬁbroblast collagen I production. Further, using A-box and HMGB1 shRNA transfected
myocytes, we found that cardiomyocyte-derived HMGB1 dramatically potentiated the HG-induced down-
regulation of IL-33 and the increase in collagen I expression in the ﬁbroblasts. The potentiating effects of the
cardiomyocytes was diminished when toll-like receptor 4 deﬁcient (TLR4−/−) ﬁbroblasts were co-cultured
with wild-type myocytes. Finally, TLR4−/−mice with diabetes had increased myocardial expression of HMGB1,
but failed to down-regulate IL-33. The diabetes-inducedmyocardial collagen deposition and cardiac dysfunction
were signiﬁcantly attenuated in TLR4−/− mice. In conclusion, our ﬁndings support a role for “cardiomyocyte
HMGB1–ﬁbroblast TLR4/IL-33 axis” in the development of myocardial ﬁbrosis and dysfunction in a murine
model of diabetes.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Diabetic cardiomyopathy (DiCM) is a complication of diabetes
mellitus (DM). It is deﬁned as myocardial dysfunction that is indepen-
dent of other known co-morbidities such as coronary artery disease or
hypertension [1–3]. Themyocardial contractile dysfunction has been at-
tributed to the detrimental effects of prolonged hyperglycemia on
cardiomyocytes. These include enhanced dependence on fatty acid
metabolism, reducedmyoﬁlament Ca++ sensitivity, mitochondrial dys-
function, oxidative stress, and apoptosis/necrosis [4–8].wson Health Research Institute,
tario N6A 4G5, Canada.Another major contributor to myocardial contractile dysfunction in
DM is ﬁbrosis, usually attributed to increased collagen deposition in the
interstitial matrix. While in the non-diabetic heart the interstitial matrix
allows for efﬁcient ventricular contraction, progressive collagen deposi-
tion can lead tomyocardial stiffening and dysfunction [1,3,9–11]. The hy-
perglycemia associated with DM results in non-enzymatic glycation of
deposited collagen, subsequent formation of advanced glycation end
products (AGEs), and collagen cross-linking which further stiffens the
myocardium and compromises cardiac function [2,12,13]. Althoughmyo-
cardialﬁbrosis is generally associatedwith advanced stages of cardiac dis-
ease [10], diffuse ﬁbrosis can be detected even in early non-symptomatic
stages of DiCM [11].
The major cardiac cell type responsible for the secretion of collagen
is the ﬁbroblast [9,12,14]. The role of cardiac ﬁbroblast in the develop-
ment of ﬁbrosis in DiCM is evidenced by the enhanced collagen
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2) challenged with high concentration of glucose (HG) [17–19]. The
precise cardiac signaling mechanisms that transduce hyperglycemia
into collagen production by cardiac ﬁbroblasts are not clear. Although
several factors have been implicated including, TGF-β, Ang II, AGEs,
and HMGB1 [2,12,20,21], neither the speciﬁc cell sources nor the recep-
tors on ﬁbroblasts have been delineated.
There appears to be signiﬁcant interactions between myocytes and
ﬁbroblasts in the myocardium, particularly regarding the impact of ﬁ-
broblasts on myocyte proliferation, development, and hypertrophy
[22]. Of particular relevance to the present study, there is also evidence
that myocytes can inﬂuence ﬁbroblast function, speciﬁcally collagen
production. For example, Ang II infusion to an isolated heart preparation
induced collagen deposition therein. Interestingly, Ang II did not affect
collagen production by isolated cardiac ﬁbroblasts, unless they were
co-cultured with cardiomyocytes [23]. More recent studies have
shown that HMGB1 plays an important role in myocardial collagen de-
position in a streptozotocin (STZ)-induced rat model of diabetes [20].
Corollary in vitro studies provided evidence indicating that 1) challenge
of isolated cardiac ﬁbroblasts or myocytes with HG increased HMGB1
production [20,24] and 2) cardiac ﬁbroblasts increased their production
of collagenwhen stimulatedwithHMGB1 [20]. Although noHG-ﬁbrosis
transduction pathwaywas identiﬁed, these latter studies provide strong
support for the possibility thatmyocytesmay impact ﬁbroblast collagen
production via HMGB1.
IL-33, a cytokine belonging to IL-1 family [25], has been shown to be
anti-hypertrophic and anti-ﬁbrotic in a ventricular pressure overload
model [26]. Based on available literature, it has been proposed that car-
diac ﬁbroblasts are a major source of IL-33 which can impact on
myocytes to prevent hypertrophy [22]. While a feasible proposal with
respect to the anti-hypertrophic effects of IL-33, ﬁbroblast–myocyte in-
teractions are directionally not plausible for the anti-ﬁbrotic effects of
IL-33. Given that ﬁbroblasts are the major source of collagen, it is
more likely thatmyocyte–ﬁbroblast interactionswouldmodulate cardi-
ac ﬁbrosis. Since we have previously shown thatmyocardial IL-33 is de-
creased in the STZ model of diabetes [27], herein we assessed whether
there is link between myocyte-derived HMGB1 and ﬁbroblast IL-33
that can lead to ﬁbrosis. Using an in vivo STZ model of DM and an
in vitro approach involving HG challenge of cardiomyocytes and ﬁbro-
blasts in co-culture,we provide evidence supporting the followingpath-
way for transduction of HG to myocardial collagen deposition in
diabetes. HG activates myocytes to produce and secrete HMGB1 which
impacts on TLR4 receptors on ﬁbroblasts reducing their IL-33 levels
and increasing their collagen production.
2. Methods
2.1. Mice
C57BL/6 mice were obtained from Charles River Canada (St. Con-
stant, PQ, Canada). TLR4 deﬁcient mice (TLR4−/−, C57BL/10 back-
ground) were purchased from Jackson Laboratories (stock# 03752).
The mice were housed in Victoria Research Labs Vivarium Service
with a 12-hour light/dark cycle and free access to rodent chow and
tap water. The mice were used for in vivo experiments and as a source
for cardiomyocytes and cardiac ﬁbroblasts for in vitro experiments.
The investigation conforms to the Guide for the Care and Use of Laborato-
ry Animals published by the US National Institutes of Health (NIH Publi-
cation, 8th Edition, 2001). The experimental procedures were reviewed
and approved by the University of Western Ontario Animal Care and
Use Committee (Protocol No. 2009-043).
2.2. In vivo STZ model of diabetes
Diabetes Mellitus (DM) was induced in 6-week-old, male C57BL/6
mice by intraperitoneal (i.p.) injection of streptozotocin [STZ; in citratebuffer, pH = 4.5; 50 mg/kg, daily for 3 consecutive days] as previously
described [28]. The sex matched littermates were injected with an
equal volume of citrate buffer as controls. DM was considered to be
induced when hyperglycemia became evident (blood glucose
levels N 22 mM). To assess whether HMGB1 plays a role in myocardial
ﬁbrosis in this model, the HMGB1 antagonist, A-box was used. The
treatment regimen consisted of intraperitoneal injections of 300 μg A-
box/mouse or vehicle (saline) every other day for 5 weeks. To assess if
TLR4, one of the receptors for HMGB1, was involved, we induced DM
in TLR4 deﬁcient mice. In some experiments recombinant mouse inter-
leukin 33 (rm IL-33)was administrated at 20mg/kg (i.p.) or the vehicle
(saline) every other day for 5 weeks [27].2.3. Isolated cardiac myocytes (CMs)
Cardiomyocytes were isolated from neonatal mouse hearts and cul-
tured as previously described [27]. In brief, the harvested hearts were
minced, digested, washed, and the cells were suspended in M199 with
10% fetal calf serum (FCS). The cardiomyocytes were enriched by a
pre-plating approach to remove contaminating cells, such as cardiac ﬁ-
broblasts (CFs) and endothelial cells which readily adhere. The non-
adherent cells were removed and cultured in M199 supplemented
with 10% FCS. After 48–72 h in culture, the cells formed a conﬂuent
monolayer consisting of 95% myocytes beating in synchrony.2.4. Isolated cardiac ﬁbroblasts (CFs)
Fibroblasts were isolated from the hearts of wild type or TLR4 deﬁ-
cient (TLR4−/−) mice and cultured by a reverse procedure as described
above for cardiomyocytes [28]. Brieﬂy, we used a bead technique to re-
move any contaminating endothelial cells [29] prior to the pre-plating
approach. This method enabled us to yield a monolayer of CFs with
95% purity, as examined with the monoclonal antibody ER-TR7 [30].2.5. CF and CM co-culture
CF and CM co-culture was established using transwell inserts [26].
Brieﬂy, CFs were grown to conﬂuence on ﬁbronectin-coated Falcon
cell culture inserts (3-μm diameter pores). Subsequently, the CF inserts
were transferred to cell culture plates containing conﬂuent monolayers
of CM. This co-culture system allowed cardiac myocytes and ﬁbroblasts
to communicate only via soluble mediators.2.6. In vitro HG model of hyperglycemia
Cultured CMs or CFs individually or in co-culture were challenged
with 30mMglucose inM199 or DMEM-F12 to simulate the hyperglyce-
mia of DM [27]. This concentration of glucose is below the level required
to induce apoptosis [17,27] or necrosis (data not shown). As an osmotic
control, the cells were incubated with 30 mMmannitol in M199.2.7. Knock down of HMGB1 with shRNA in CFs
HMGB1 small hairpin RNA (HMGB1 shRNA) plasmid and a negative
control shRNA plasmid were purchased from Santa Cruz biotechnology,
Inc. The transfection of shRNA plasmid into cardiac myocytes was per-
formed using Lipofectamine 2000 (Invitrogen) according to the
manufacturer's instructions. Brieﬂy, neonatal cardiomyocytes were
plated in 24-well plates in complete M199. Subsequently, the
cardiomyocytes were transfected with HMGB1 shRNA plasmid or nega-
tive control [31]. Forty eight hours after the shRNA transfection, the
cardiomyocytes were ready for co-culture with CFs.
2077A. Tao et al. / Biochimica et Biophysica Acta 1852 (2015) 2075–20852.8. Over-expression of IL-33 in CFs
To probe for a role of IL-33, we over-expressed IL-33 in CFs by
transfection of the cells with pCMV6-Kan/Neo containing mouse IL-
33 cDNA using LipofectamineTM2000 transfection reagent. As a con-
trol, CFs were transfected with empty vector pCMV6KN. The over ex-
pression of IL-33 was conﬁrmed by Western blot 48 h after the
transfection.Fig. 1.Myocardial expression of HMGB1 increases while that of IL-33 decreases in the STZ mo
(Sham)were treatedwith vehicle (see text for details). Hearts were harvested at 2 and 4weeks
were assessedwith immunoﬂuorescence staining (A) andWestern blot (B). A. HMGB1 is staine
both Sham and STZ mice. (Magniﬁcation: 40×). B. Representative blots are shown above and d2.9. Generation of A-box
The HMGB1 inhibitor, A box was generated as previously de-
scribed [32]. Brieﬂy, plasmid (pGEX-5X-2) containing the coding
region for A-box (a gift of Dr C-Y Wang, Medical College of
Georgia, USA) or control plasmid was transformed into Escherichia
coli BL21 (DE3) and incubated in 2YT medium containing ampicil-
lin (100 mg/mL) for 3–4 h at 37 °C. Fusion protein A-box or GSTdel of diabetes. C57BL/6 mice were injected with streptozotocin (STZ) while control mice
after induction of hyperglycemia (plasma glucose N 22mM). HMGB1 and IL-33 expression
d green while IL-33 is stained red. Images are representative of three different hearts from
ensitometric analysis below. n = 3 in duplicate, *p b 0.05 compared to Sham.
2078 A. Tao et al. / Biochimica et Biophysica Acta 1852 (2015) 2075–2085was induced by 0.5 mM isopropyl D-thiogalactopyranoside and pu-
riﬁed by Glutathione Sepharose afﬁnity column. The puriﬁed A-box
or GST was passed over polymyxin B columns to remove any con-
taminating LPS.2.10. Sirius red staining
Hearts were ﬁxed with 10% formalin before being embedded in
parafﬁn. Tissue sections (5 μM) were de-parafﬁnized following a se-
ries of ethanol washes. Tissue sections were stainedwith picro-Sirius
red satin solution for 1 h at room temperature. Then slides were
washed in two changes of acidiﬁed water (0.5% acetic acid) for
2 min, and excess water was removed by blotting. Finally, the sec-
tions were dehydrated in 100% alcohol and cleared in xylene and
mounted with cover glass [33]. When viewed under bright-ﬁeld mi-
croscope the collagen appeared red on a yellow background. The pic-
tures taken of the slide (5 ﬁelds per slide) were analyzed using Sigma
Scan software.Fig. 2. Inhibition of HMGB1 or administration of exogenous IL-33 preventsmyocardial ﬁbrosis a
as described in Fig. 1. Oneweek after development of hyperglycemia, the STZmicewere subjecte
33. Subsequently,myocardial levels of collagenwere assessedwith Sirius red (A) or immunoﬂuo
lower panel quantitative analyses (using Image J software). C. Representative blots are shown
#p b 0.05 compared to STZ. D & E. Myocardial function was evaluated using a mouse pressure-
were obtained. Representative pressure-volume loops are shown inD and quantitation of ESPVR
to STZ.2.11. Immunoﬂuorescence staining
Cardiac tissuewas ﬁxedwith 10% formalin. The specimenswere proc-
essed for parafﬁn embedding. After deparafﬁnization, rehydration, and
antigen retrieval with sodium citrate (pH = 6.0), tissue sections were
probed with primary antibodies targeting mouse HMGB1 (Abcam, Cam-
bridge, MA, USA), IL-33 (R&D Systems Inc, Minneapolis, MN, USA), and
collagen I (Abcam, Cambridge, MA, USA). The expression of speciﬁc pro-
teins was detected using a secondary antibody conjugated with FITC or
Texas-red ﬂuorescence and assessed using immunoﬂuorescence micros-
copy (Zeiss Axiovert 200 M) [32]. When quantitation was required, the
relative intensity of the ﬂuorescence in each image was assessed using
Image J software.
2.12. Western blot
Western blot was used for assessment of protein expression as pre-
viously described [32,34]. In brief, tissue or cell lysates were resolved on
SDS-polyacrylamide gels and transferred to polyvinylidine ﬂuoridend improvesmyocardial function in the STZmodel of diabetes. Mice were treatedwith STZ
d to long-term treatment (5weeks)with either A-box (HMGB1 inhibitor) or exogenous IL-
rescence staining (B) and byWestern blot (C). For A andB, upper-panel depicts images and
above and densitometric analysis below. n = 3 in duplicate. *p b 0.05 compared to Sham;
volume loop analysis system from which systolic (ESPVR) and diastolic (EDPVR) function
and EDPVR in E. Fivemice in each group, *p b 0.05 compared to Sham; #p b 0.05 compared
2079A. Tao et al. / Biochimica et Biophysica Acta 1852 (2015) 2075–2085(PVDF)membranes. After blockingwith 5%nonfatmilk, themembranes
were immunoblotted using anECLdetection system. Primary antibodies
against mouse HMGB1 (Abcam, Cambridge, MA, USA), IL-33 (Enzo LifeFig. 3. Cardiomyocyte (CM)-derivedHMGB1potentiates high glucose (HG)-induced down-regu
mannitol (Mtl; 30mM) for up to 48 h. At the times indicated, the cardiomyocytes and supernat
measured withWestern blot and ELISA, respectively. n = 3 in duplicate. *p b 0.05 compared to
vested for expression of IL-33 (Western blot) 48 h later. n = 3 in duplicate. *p b 0.05, comp
cardiomyocytes were challenged with HG. A-box was used to inhibit HMGB1. n = 3 in duplic
alone or in co-culture with myocytes were challenged with HG. shHMGB1 was used to down-r
n = 3 in duplicate, *p b 0.05 compared to HG only; #p b 0.05 compared to myocytes + HG.Sciences, Plymouth Meeting, PA, USA), Collagen I (Abcam, Cambridge,
MA, USA), and β-actin (Santa Cruz Biotech, Inc, Dallas, TX, USA) were
used to probe for their speciﬁc proteins. HMGB1 secretion by cardiaclation of cardiacﬁbroblast (CF) IL-33. A. Cardiomyocyteswere treatedwithHG (30mM) or
ants were harvested. Intracellular (upper-panel) and released HMGB1 (lower-panel) were
controls. B. HMGB1 (1 μg/ml) was added to CFs with or without HG and the CFs were har-
ared to control (DMEM), #p b 0.05 compared to HG. C. CFs alone or in co-culture with
ate. *p b 0.05 compared to HG only; #p b 0.05 compared to cardiomyocytes + HG. D. CFs
egulate HMGB1 in myocytes; inset conﬁrms down-regulation of HMGB1 with shHMGB1.
2080 A. Tao et al. / Biochimica et Biophysica Acta 1852 (2015) 2075–2085myocytes wasmeasured in supernatants using a 2-step sandwich ELISA
kit according to the manufacturer's instructions.
2.13. Myocardial function assessment
Amouse pressure-volume loop analysis systemwas used for assess-
ment of myocardial function [32]. Brieﬂy, six weeks after induction of
diabetes, the Sham or STZ mice were anesthetized with ketamine
(150 mg/kg) and xylazine (5 mg/kg) subcutaneously. A Millar tip con-
ductance catheter (Model SPR-893, 1.4 Fr.) was advanced into the left
ventricle (LV) via the right carotid artery after baseline zero reference
was obtained by placing the sensor in normal saline. After record the
basal hemodynamic parameters, a series of pressure-volume loops
were generated by occlusion of the inferior caval vein using a Power-
Lab system connected to the Millar catheter. Left ventricular (LV) end-
systolic pressure volume relation (ESPVR) and LV end-diastolic
pressure volume relation (EDPVR) were determined from the
pressure-volume loop data with a ChartPro Software (AD Instruments
Inc, Colorado Springs, CO, USA).
2.14. Statistical analysis
All datawere expressed asmean±SEM. Statistical analysis was per-
formed using ANOVA and student's t-test (with a Bonferroni correction
for multiple comparisons).
3. Results
3.1. Myocardial expression of HMGB1 and IL-33 in mice with DM
Fig. 1 depicts myocardial expression of HMGB1 and IL-33 using im-
munoﬂuorescence staining and Western blot in the murine STZ model
of DM. Myocardial expression of HMGB1 was increased, while that of
IL-33 was decreased at 2 and 4 weeks after achieving a hyperglycemicFig. 4. Role of cardiomyocyte HMGB1 and ﬁbroblast IL-33 in collagen production. A. Fibroblasts
harvested for assessment of collagen I expression. A-box was used to inhibit HMGB1. n = 3, in
pared to myocytes + HG. B. Wild type and IL-33 over-expressing ﬁbroblasts were treated with
expression was assessed with Western blot. n = 3 in duplicate. *p b 0.05 compared to DMEM;state (plasma glucose N 22mM). Immunoﬂuorescence staining indicat-
ed that HMGB1 and IL-33 were not co-localized (merged image in
Fig. 1A); HMGB1 was primarily localized to the myocytes, while IL-33
was localized to the interstitial ﬁbroblasts.3.2. Role of HMGB1 and IL-33 in induction of myocardial ﬁbrosis and
dysfunction in DM
Mice developed cardiomyopathy six weeks after the induction of
DM as indicated by increased myocardial ﬁbrosis and dysfunction
(Fig. 2). Initially,ﬁbrosiswas assessed using generalized staining for col-
lagen with Sirius red. The percent of myocardial area occupied by colla-
gen increased in the diabetic myocardium (Fig. 2A). Both collagen I and
III deposition have been reported in myocardium in various rodent
models of DM [18,20,35]. Thus, we measured collagen I as a prototype.
Both immunoﬂuorescent (Fig. 2B) and Western blot (Fig. 2C) ap-
proaches indicate that collagen I deposition increased in the myocardi-
um of the diabetic mice. In addition to increased ﬁbrosis in the STZ
model of diabetes, myocardial function was also compromised
(Fig. 2D & E). As shown in Fig. 2E, there was a decrease in myocardial
contractility (decrease in ESPVR) and diastolic function (increase in
EDPVR) noted in the STZ model of diabetes.
To assess whether the increase in HMGB1 was contributing to the
myocardial collagen deposition and dysfunction, HMGB1 was inhibited
by long-term administration of the inhibitor, A-box. As shown in Fig. 2,
inhibition of HMGB1 attenuated themyocardial collagen deposition and
improvedmyocardial function. A-box had no effect onmyocardial func-
tion in naïve mice (data not shown).
To determine whether DM-induced down-regulation of IL-33 con-
tributes to the pathogenesis of diabetic cardiomyopathy, exogenous
IL-33 was administered. As shown in Fig. 2, long-term administration
of IL-33 substantially attenuated the myocardial collagen deposition
and improved myocardial function. Exogenous IL-33 had no effect on
myocardial function in naïve mice (data not shown).or myocyte/ﬁbroblast co-cultures were challenged with HG for 48 h, and ﬁbroblasts were
duplicate. *p b 0.05 compared to control; #p b 0.05 compared to HG only; +p b 0.05 com-
HG or HG + HMGB1 for 72 h; inset conﬁrms IL-33 over-expression. Fibroblast collagen I
#p b 0.05 compared to HG; +p b 0.05 compared to empty vector.
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ﬁbroblast IL-33
Challenge of isolated cardiomyocytes with HG increased HMGB1 ex-
pression and secretion (Fig. 3A). As reported by others [20,24], chal-
lenge of isolated cardiac ﬁbroblasts with HG modestly increased
HMGB1 production, the effects were minimal compared to those
noted in myocytes (data not shown). In addition, we could not detect
intracellular levels of IL-33 in naïve cardiomyocytes (data not shown),
again in keeping with previous studies [26]. However, IL-33 levels in ﬁ-
broblasts were detectable, and were slightly decreased by HG (Fig. 3B–
D). Taken together, the in vitro approach usingHG tomimic hyperglyce-
mia seems to recapitulate the in vivo STZ model of diabetes (Fig. 1).
The HG-induced down regulation of CF IL-33 was signiﬁcantly en-
hanced by exogenous HMGB1 (Fig. 3B). Further, challenge of myocyte/
ﬁbroblast co-cultures with HG resulted in a substantial reduction of ﬁ-
broblast IL-33 when compared to HG challenge alone (Fig. 3C & D).
The potentiating effect of myocytes on down-regulation of IL-33 in ﬁ-
broblast was abrogated, if the co-cultures included the HMGB1Fig. 5. TLR4−/− ﬁbroblasts are unresponsive to myocyte-derived HMGB1 with respect to do
(TLR4−/− CF) were treated with HG in the absence or presence of wild type (WT) myocytes. TL
of IL-33 or collagen I expression, respectively. Representative Western blots above and densito
myocytes). B. TLR4−/− CFs were treated with HG in the absence or presence of HMGB1 and th
spectively. Representative Western blots above and densitometric analyses below. n = 3 in duinhibitor, A-box (Fig. 3C) or the myocytes were transfected with
HMGB1 shRNA prior to co-culture (Fig. 3D). These latter observations
indicate that in the in vitro HG model, cardiac myocytes can potentiate
the down-regulation of IL-33 in cardiac ﬁbroblasts; an effect mediated
by myocyte-derived HMGB1.
3.4. Cardiomyocyte-derived HMGB1 potentiates HG-induced collagen
production by cardiac ﬁbroblasts
As shown in Fig. 4A, HG challenge of ﬁbroblasts slightly increased
collagen I expression. The effect was signiﬁcantly enhancedwhen ﬁbro-
blasts were co-cultured with myocytes; the potentiating effect was ab-
rogated by the HMGB1 inhibitor, A-box. Further, the increase in
collagen I expression by ﬁbroblasts induced by HG was potentiated by
exogenous HMGB1 (Fig. 4B; shaded bars). As shown in Fig. 4B, over-
expression of IL-33 in ﬁbroblasts substantially blunted the HG-
induced collagen I production. More importantly, over-expression of
IL-33 in ﬁbroblasts abrogated the HMGB1-induced potentiating effect
on HG-induced collagen I production. Collectively, our results indicate,wn-regulation of IL-33 and increased collagen production. A. TLR−/− cardiac ﬁbroblasts
R4−/− CFs were harvested 24 h or 48 h after challenge with HG for assessment evaluation
metric analyses below. n = 3 in duplicate, *p b 0.05 compared to control (without HG or
e CFs were harvested 24 or 48 h later for assessment of IL-33 or collagen I expression, re-
plicate, *p b 0.05 compared to ﬁbroblasts without HG or myocytes.
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cardiomyocytes can down-regulate IL-33 in ﬁbroblasts, thereby poten-
tiating collagen I production.
3.5. Role of TLR4 in myocyte–ﬁbroblast interactions and diabetic
cardiomyopathy
To assesswhether cardiomyocyte-derivedHMGB1 is acting on ﬁbro-
blast TLR4, we used ﬁbroblasts derived from TLR4 deﬁcient (TLR4−/−)
mice. Challenge of TLR4−/− ﬁbroblasts with HG slightly decreased IL-
33 expression and increased collagen I production (Fig. 5A); responses
similar to those noted in wild type ﬁbroblasts (Figs. 3 & 4). However,
when TRL4−/− ﬁbroblasts were co-cultured with wild type myocytes,
the myocyte-induced potentiating effect on down-regulation of ﬁbro-
blast IL-33 and increase in collagen production was negated (compare
Figs. 5A to 3C & 4A). Further, exogenous HMGB1 did not elicit a poten-
tiating effect on HG-induced down regulation of IL-33 and increase in
collagen production in TLR4−/− ﬁbroblasts (Fig. 5B to 3B & 4B).
The role of the HMGB1/TLR4 axis in the development of DM in vivo
was assessed by using TLR4−/−mice in the STZmodel. Two weeks after
the induction of DM, myocardial levels of HMGB1 were increased in
bothwild type (WT) and TLR4−/−mice (Fig. 6). However, while the ex-
pected decrease in IL-33 was noted in WT mice, it was not evident inFig. 6. TLR4−/−mice do not respond to STZ-induced diabetes with a decrease in IL-33 expression.
Fig. 1.Heartswereharvested at 2weeks after development of hyperglycemia.HMGB1and IL-33exp
stained green while IL-33 is stained red. Images are representative of three different hearts from b
densitometric analysis below. *p b 0.05 compared to WT-vehicle; #p b 0.05 compared to TLR4−/−TLR4−/−mice. Further, as predicted fromFigs. 1 and 2,myocardialﬁbro-
sis (Fig. 7A & B) and dysfunction (Fig. 7C) were evident in WT mice.
However, in TLR4−/− mice, the STZ-induced myocardial ﬁbrosis and
dysfunctionwere substantially blunted. Collectively, these observations
indicate that the HMGB1/TLR4 axis plays a major role in the myocardial
ﬁbrosis and dysfunction in the STZ model of diabetes.
4. Discussion
One of the structural derangements of diabetic cardiomyopathy is
the excessive deposition of collagen leading to myocardial stiffening
and dysfunction [1,3,9,10,12]. The hyperglycemia of diabetes has been
proposed asmajor causative factor in the development ofmyocardial ﬁ-
brosis [1]. In accord with this view, isolated cardiac ﬁbroblasts have
been shown to produce collagens when challenged with high concen-
trations of glucose (HG) [18–20] aswell as references therein. Of the po-
tential proﬁbrotic mediators proposed, a recent study has provided
compelling evidence implicating HMGB1 [20]. Speciﬁcally, myocardial
HMGB1 expression was increased in a rodent STZ model of diabetes
and blockade of HMGB1 blunted the STZ-induced ﬁbrosis. In the same
study, HG challenge of isolated cardiac ﬁbroblasts induced collagen pro-
duction; a response dependent, in part, onHMGB1. In the present study,
we expand on these initial observations by using in vivo and in vitroWild type (WT) and TLR4−/−mice were treated with STZ to induce diabetes as described in
ressionwas assessedby immunoﬂuorescence staining (A) andWesternblot (B). A.HMGB1 is
oth Sham and STZ mice. (Magniﬁcation: 40×). B. Representative blots are shown above and
-vehicle.
Fig. 7. The STZ-induced myocardial ﬁbrosis and dysfunction are attenuated in TLR4−/−mice. Wild type (WT) and TLR4−/−mice were treated with STZ to induce diabetes as described in
Fig. 1. Myocardial collagen productionwas assessed by Sirius red staining (A) orWestern blot (B) at 6weeks after development of hyperglycemia. n= 5, *p b 0.05 compared to respective
controls, #p b 0.05 compared to WT-STZ. C. Myocardial systolic (ESPVR) and diastolic function (EDPVR) were assessed by pressure-volume loop analysis. n = 5, *p b 0.05 compared to
respective controls, #p b 0.05 compared to WT-STZ.
2083A. Tao et al. / Biochimica et Biophysica Acta 1852 (2015) 2075–2085approaches to address a potential extracellular communication path-
way involved in transduction of hyperglycemia into myocardial ﬁbrosis
and dysfunction. Speciﬁcally, our ﬁndings support the following scenar-
io: in response to elevated levels of glucose, cardiomyocytes can release
HMGB1 which, in turn, impacts on TLR4 receptors on adjacent ﬁbro-
blasts, decreasing their IL-33 expression and increasing their collagen
production.
Extracellular HMGB1 is a cytokine that is considered a prototypic
“alarmin” or “damage-associated molecular pattern” (DAMP) molecule
that can be secreted bydistressed, yet viable, cells [36]. SecretedHMGB1
is recognized by the innate immune systemwhich initiates an appropri-
ate inﬂammatory response. HMGB1 has been implicated in the patho-
genesis of a broad range of inﬂammatory diseases, including arthritis
[37], endotoxemia [32], ischemia/reperfusion [38], atherosclerosis
[39], as well as diabetes [24]. It has also been reported to play an impor-
tant role in a variety of ﬁbrotic pathologies [40], including diabeticmyo-
cardial ﬁbrosis and dysfunction [20]. However, the speciﬁc cells and
receptors involved in HMGB1 signaling have not been identiﬁed. In
the present study, we provide evidence supporting a myocyte–ﬁbro-
blast interaction involving myocyte-derived HMGB1 enhancing colla-
gen production by adjacent ﬁbroblasts (Fig. 4). Further, we show that
TLR4 is critical for STZ-induced myocardial ﬁbrosis and dysfunction(Figs. 6 and 7) and that an HMGB1 interaction with TLR4 on ﬁbroblasts
is required to elicit collagen production (Fig. 5).
Extracellular HMGB1 can exert its effects on cells via binding to either
RAGE, CXCR4, as well as several TLRs (e.g. TLR4, TLR2, and TLR9) [36,40,
41]. The results presented herein indicating that HMGB1 ligation of the
TLR4 recptors on ﬁbroblasts is a prerquisite for collagen production
(Fig. 5). Previous studies have implicated a role for either HMGB1 or
TLR4, or both in development of ﬁbrosis in various pathologies
(e.g., ischemia/reperfusion, diabetes) and target organs (e.g., heart, kid-
ney, liver) [17,40–43]. However, direct evidence for an HMGB1/TLR4
pathway and the speciﬁc cells involved has not been established. Herein,
in a murine model of diabetes, we provide evidence linking cardiomyo-
cyte derived HMGB1 and ﬁbroblast TLR4 as an important intracardiac
signaling pathway in the development of ﬁbrosis and dysfunction
(Figs. 5–7). However, since blockade of the HMGB1/TLR4 pathway failed
to completely prevent the myocardial ﬁbrosis and dysfunction (Fig. 7),
another pathway, such as HMGB1/TLR2, may be involved in this pathol-
ogy. Alternatively, The AGE/RAGE pathway has been implicated in the
cardiac ﬁbrosis, i.e., AGEs can be generated by glycation of collagen as a
result of the chronic hyperglycemia of diabetes and interact with RAGE
to induce ﬁbrosis [12]. Indeed, ﬁbroblasts isolated from diabetic mice
(genetically-induced; db/db) have increased levels of RAGE [16].
2084 A. Tao et al. / Biochimica et Biophysica Acta 1852 (2015) 2075–2085Interestingly, although RAGE can serve as a receptor for HMGB1, it may
simply have a role in presenting HMGB1 to TLR4 [44]. Further studies
are warranted to address a potential interaction between these two
pathways in generating cardiac ﬁbrosis in diabetes.
IL-33 is amember of the IL-1 cytokine family that can exert its effects
either intracellularly (transcriptional repression) or extracellularly
(serving as an alarmin) [45]. IL-33 has been implicated in ﬁbrosis, either
as part of a normal repair process in the gastrointestinal tract [46] or ex-
cessive pathologic ﬁbrosis in the skin [47]. By contrast, in the heart
ﬁbroblast-derived IL-33 serves to prevent cardiac hypertrophy and ﬁ-
brosis in a murine pressure overload model (transverse aortic constric-
tion) [26]. Our results are more in line with the latter study, in that, in a
murine STZ model of diabetes IL-33 seems to function as a anti-ﬁbrotic
cytokine. An explanation for these discordant results is not readily ap-
parent and further studies are warranted to better understand the spe-
ciﬁc conditions under which IL-33 exerts either pro- or anti-ﬁbrotic
effects.
In conclusion, the results of the present study are consistentwith the
following scenario. Hyperglycemia of diabetes can induce a cellular
stress in cardiac myocytes resulting in the release of the DAMP,
HMGB1. Interstitial HMGB1 interacts with the TLR4 receptor on adja-
cent ﬁbroblasts decreasing their expression of IL-33 and increasing
their production of collagen. The excessive collagen accumulation re-
sults in myocardial dysfunction.
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